The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.
Koukeo PhommasoneFrank van LethMallika ImwongGisela HenriquesTiengkham PongvongsaBipin AdhikariThomas J PetoCholrawee PromnarateMehul DhordaPasathorn SirithiranontMavuto MukakaPimnara PeerawaranunNicholas P J DayFrank CobelensArjen M DondorpPaul N NewtonNicholas J WhiteLorenz von SeidleinMayfong MayxayPublished in: Malaria journal (2020)
A 14-day course of primaquine in addition to a DP-MDA was safe, well-tolerated, and prevented recurrent asymptomatic P. vivax infections. Long follow-up for up to 12 months is required to capture all recurrences following the treatment of asymptomatic vivax infection. To eliminate all malarias in settings where P. vivax is endemic, a full-course of an 8-aminoquinolines should be added to MDA to eliminate all malarias. Trial registration This study was registered with ClinicalTrials.gov under NCT02802813 on 16th June 2016. https://clinicaltrials.gov/ct2/show/NCT02802813.
Keyphrases
- plasmodium falciparum
- breast cancer cells
- computed tomography
- study protocol
- gold nanoparticles
- clinical trial
- image quality
- quantum dots
- high resolution
- magnetic resonance imaging
- randomized controlled trial
- phase iii
- cell cycle arrest
- cell proliferation
- positron emission tomography
- dual energy
- magnetic resonance
- mass spectrometry
- cell death
- open label
- combination therapy
- solid phase extraction
- double blind